RXi Pharmaceuticals is a clinical-stage company developing therapeutics based on its self-delivering RNAi (sd-rxRNA®) platform and Samcyprone, a topical immunomodulator. Co.'s clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone, for the treatment of warts. Co.'s development programs also include cell-based cancer immunotherapy. Co.'s RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its topical immunotherapy agent, Samcyprone, treats diseases by inducing, enhancing or suppressing an immune response in the skin. The RXII stock yearly return is shown above.
The yearly return on the RXII stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RXII annual return calculation with any dividends reinvested as applicable (on ex-dates).
|